**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a case report, 3 patients (2 women and one man) aged 37−78 years were described, of whom a 48-year-old woman developed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during treatment with paclitaxel and doxorubicin for breast cancer, a 37-year-old man developed SARS-CoV-2 infection and influenza-A virus infection during immunosuppressive treatment with tacrolimus and unspecified antineoplastics for hepatocellular carcinoma (HCC), and a 78-year-old woman exhibited lack of efficacy during treatment with cefoperazone/sulbactam and linezolid for double pneumonia in China \[*dosages and routes not stated*\].

A 48-year-old woman, who had breast cancer, was admitted for radiotherapy on 21 December 2019. On 25 June 2019, she underwent a modified radical mastectomy of the right breast, and received 6 cycles of paclitaxel and doxorubicin after the surgery. On 24 January 2020 (after 4 weeks of radiotherapy), she developed fever accompanied by cough. A chest CT scan showed slight interstitial abnormalities in both lower lungs, indicating a possibility of viral pneumonia. In a throat swab sample using the real-time reverse transcription polymerase chain reaction (RT-PCR) method, the SARS-CoV-2 infection was confirmed by positive detection of the virus. The laboratory results revealed decreased WBC count, lymphocyte count and natural killer cells in the blood. Based on these findings, a diagnosis of mild SARS-CoV-2 infection was made on 26 January 2020. Therefore, she was shifted to an isolation ward. She received off-label treatment with ceftriaxone. As a result, her symptoms resolved two days later. After her symptoms resolved, ceftriaxone therapy was stopped. On 30 January 2020, the chest CT scan also suggested recovery from COVID-19. However, the virus sustained in the throat swab samples for several days. She was then transferred to an another isolation ward after discharge from the hospital. On 13 February 2020, the SARS-CoV-2 infection cleared from the throat swab sample, and she recovered completely.

A 78-year-old woman was admitted with malaise, fatigue and poor appetite on 18 January 2020. Her medical history was significant for chronic B-cell lymphocytic leukemia (B-CLL) for 5 years. She also had cardiovascular disease, hypertension and chronic obstructive pulmonary disease (COPD) for more than 10 years. On 23 February 2014, she received percutaneous coronary intervention. She had been receiving atorvastatin, aspirin, nifedipine and indapamide to control BP. On admission, a chest CT scan showed bilateral patchy shadowing indicating double pneumonia on 19 January 2020. She was diagnosed with double pneumonia, COPD, hypertension, B-CLL and coronary heart disease. She was treated with cefoperazone/sulbactam and linezolid concomitantly with oseltamivir and caspofungin for double pneumonia. Due to the immunocompromised state and the severe pulmonary infection, the initial empirical antimicrobial treatment covered influenza virus, bacteria and fungi. Subsequently, her pneumonia progressed. On 25 January 2020, she developed dyspnoea, fever and shortness of breath. In a throat swab sample, the SARS-CoV-2 was found positive by RT-PCR method. She was then transferred to the ICU and started receiving high flow humidification oxygen inhalation therapy (non-invasive ventilation) and off-label treatment with methylprednisolone 40mg daily. After 5 days of therapy in the ICU, dyspnoea and hypoxia improved, and she was transferred to an isolation ward on 31 January 2020. However, methylprednisolone and high flow humidification oxygen inhalation combination therapy was continued. Despite the non-invasive ventilation and cefoperazone/sulbactam and linezolid therapy for double pneumonia, she died due to respiratory failure on 10 February 2020. The older age, multiple underlying diseases and severe pulmonary infection were considered to be contributory factors in her death. As a result, lack of efficacy with cefoperazone/sulbactam and linezolid was considered.

A 37-year-old man, who had upper abdominal intermittent pain for more than 3 months, was admitted on 14 January 2020. One day prior to the admission, a space-occupying lesion was found in the liver. He was a hepatitis-B virus carrier for more than 19 years; however, he was not receiving antiviral treatment. After admission, he was diagnosed with chronic hepatitis-B and HCC. On 16 January 2020, he received unspecified antineoplastics \[chemotherapy\] through transcatheter arterial chemoembolisation. On 20 January 2020, he underwent an allogeneic liver transplantation for a better prognosis. Post-surgery, he started receiving immunosuppressive treatment with tacrolimus concomitantly with immune globulin \[immunoglobulin\] and an anti-viral treatment with entecavir. On 30 January 2020, he developed fever accompanied by a cough. On 31 January 2020 and 1 Febuary 2020, the nucleic acids of influenza-A virus and SARS-CoV-2 were found positive in throat swab samples. As a result, a diagnosis of SARS-CoV-2 and influenza-A virus infection secondary to the tacrolimus therapy and unspecified antineoplastics was made on 1 February 2020. He was transferred to the ICU on 2 February 2020 due to dyspnoea. The chest X-ray revealed bilateral patchy shadowing indicating COVID-19. In the ICU, he received an off-label treatment with umifenovir \[arbidol\], oseltamivir, imipenem, moxifloxacin, cilastatin, caspofungin and methylprednisolone 40mg daily along with high-flow humidification oxygen inhalation. Subsequently, he received an off-label treatment with combination of anti-infectives \[antimicrobial\] therapy due to increased plasma level of 1-3-β-D polyglucosan and detection of influenza-A virus with SARS-CoV-2 infection. As a result, his symptoms improved two days later. On 4 Febuary 2020, he was transferred to an isolation ward and received the same treatment, which was administered in the ICU. On 18 Febuary 2020, lung CT scan revealed remission of the pneumonia despite the right pleural effusion. Therefore, his therapy with umifenovir, oseltamivir, imipenem, moxifloxacin, cilastatin, caspofungin and methylprednisolone was stopped on 19 Febuary 2020. Subsequently, the lymphocyte count decreased. However, the virus sustained in the throat swab sample test. Therefore, he remained hospitalised. On 10 March 2020, his SARS-CoV-2 and influenza-A virus infection cleared from the throat swab samples, and he was discharged.
